The Supreme Court rules against Novo Nordisk (NVO +1.2%) in an IP dispute with generics drugs...

|By:, SA News Editor

The Supreme Court rules against Novo Nordisk (NVO +1.2%) in an IP dispute with generics drugs maker Caraco over Novo's Prandin diabetes drug. The verdict allows Caraco to sue Novo to narrow the patent description it gives to the FDA so that it only covers one use rather than three, thus allowing Caraco to enter the market.